OBJECTIVE: The authors sought to empirically test whether relative health stock, a measure of patients' sense of loss in their health due to illness, influences the treatment decisions of patients facing life-threatening conditions. Specifically, they estimated the effect of relative health stock on advanced cancer patients' decisions to participate in phase I clinical trials. METHOD: A multicenter study was conducted to survey 328 advanced cancer patients who were offered the opportunity to participate in phase I trials. The authors asked patients to estimate the probabilities of therapeutic benefits and toxicity, their relative health stock, risk preference, and the importance of quality of life. RESULTS: Controlling for health-related quality of life, an increase in relative health stock by 10 percentage points reduced the odds of choosing to participate in a phase I trial by 16% (odds ratio = 0.84, 95% confidence interval = 0.72, 0.97). CONCLUSION: Relative health stock affects advanced cancer patients' treatment decisions.
OBJECTIVE: The authors sought to empirically test whether relative health stock, a measure of patients' sense of loss in their health due to illness, influences the treatment decisions of patients facing life-threatening conditions. Specifically, they estimated the effect of relative health stock on advanced cancerpatients' decisions to participate in phase I clinical trials. METHOD: A multicenter study was conducted to survey 328 advanced cancerpatients who were offered the opportunity to participate in phase I trials. The authors asked patients to estimate the probabilities of therapeutic benefits and toxicity, their relative health stock, risk preference, and the importance of quality of life. RESULTS: Controlling for health-related quality of life, an increase in relative health stock by 10 percentage points reduced the odds of choosing to participate in a phase I trial by 16% (odds ratio = 0.84, 95% confidence interval = 0.72, 0.97). CONCLUSION: Relative health stock affects advanced cancerpatients' treatment decisions.
Authors: S Yousuf Zafar; Stewart C Alexander; Kevin P Weinfurt; Kevin A Schulman; Amy P Abernethy Journal: Support Care Cancer Date: 2008-09-19 Impact factor: 3.603
Authors: Jacquelyn Slomka; Georgios Kypriotakis; John Atkinson; Pamela M Diamond; Mark L Williams; Damon J Vidrine; Roberto Andrade; Roberto Arduino Journal: AIDS Patient Care STDS Date: 2012-06-11 Impact factor: 5.078
Authors: Linda Fleisher; Dominique G Ruggieri; Suzanne M Miller; Sharon Manne; Terrance Albrecht; Joanne Buzaglo; Michael A Collins; Michael Katz; Tyler G Kinzy; Tasnuva Liu; Cheri Manning; Ellen Specker Charap; Jennifer Millard; Dawn M Miller; David Poole; Stephanie Raivitch; Nancy Roach; Eric A Ross; Neal J Meropol Journal: Patient Educ Couns Date: 2014-04-21
Authors: Neal J Meropol; Brian L Egleston; Joanne S Buzaglo; Al B Benson; Donald J Cegala; Michael A Diefenbach; Linda Fleisher; Suzanne M Miller; Daniel P Sulmasy; Kevin P Weinfurt Journal: Cancer Date: 2008-12-15 Impact factor: 6.860
Authors: Neal J Meropol; Brian L Egleston; Joanne S Buzaglo; Andrew Balshem; Al B Benson; Donald J Cegala; Roger B Cohen; Michael Collins; Michael A Diefenbach; Suzanne M Miller; Linda Fleisher; Jennifer L Millard; Eric A Ross; Kevin A Schulman; Allison Silver; Elyse Slater; Nicholas Solarino; Daniel P Sulmasy; Jonathan Trinastic; Kevin P Weinfurt Journal: Cancer Date: 2013-01-18 Impact factor: 6.860
Authors: Joanne S Buzaglo; Jennifer L Millard; Caroline G Ridgway; Eric A Ross; Susan P Antaramian; Suzanne M Miller; Neal J Meropol Journal: J Cancer Educ Date: 2007 Impact factor: 2.037
Authors: Yu-Ning Wong; Neal J Meropol; William Speier; Daniel Sargent; Richard M Goldberg; J Robert Beck Journal: Cancer Date: 2009-05-15 Impact factor: 6.860